Recce Pharmaceuticals Ltd. announced the China National Intellectual Property Administration has formally granted Recce a new family two patent, Copolymer and Method for Treatment of Bacterial Infection, for its anti-infectives, with expiry in 2035. This is the final of Recce?s wholly-owned patents granted for family two, with the Company now patent-protected in all major pharmaceutical markets globally. The Chinese patent claims relate to RECCE 327 (R327) and RECCE 529 (R529), including their methods of manufacture, administration, and application to treat a broad range of common human infections.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.595 AUD | +2.59% | +2.59% | +11.21% |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+11.21% | 79.06M | |
+42.60% | 748B | |
+34.11% | 598B | |
-6.23% | 356B | |
+18.08% | 325B | |
+4.42% | 283B | |
+17.19% | 245B | |
+9.03% | 211B | |
-4.09% | 209B | |
+2.15% | 166B |
- Stock Market
- Equities
- RCE Stock
- News Recce Pharmaceuticals Ltd
- Recce Pharmaceuticals Ltd Receives New Patent in China for RECCE Anti-Infectives from China National Intellectual Property Administration